JPRN-jRCT2080222257未知1 期
Phase 1, Open-label Study to Assess the Safety, Tolerability, and Pharmacokinetics of DS-8895a in Subjects with Advanced Solid Tumor
DAIICHISANKYO Co.,Ltd.0 个研究点目标入组 38 人开始时间: 2013年10月18日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 发起方
- 入组人数
- 38
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Advanced solid tumor that is refractory to standard treatment, or for which no standard treatment is available.
- •- ECOG Performance Status(PS)of 0 or 1
排除标准
- •- Have any of the following concomitant disease or had the history of having following disease within 6 months before enrollment:
- •Cardiac failure (NYHA >= ClassIII), myocardial infarction, cerebral infarction, unstable angina, arrhythmia requiring treatment, coronary-artery/peripheral artery bypass surgery, cerebrovascular disease, pulmonary thromboembolism, deep-vein thrombosis or clinically severe thromboembolic events, or clinically severe pulmonary disease (eg, interstitial pneumonia, pulmonary fibrosis, radiation pneumonia, drug induced pneumonia)
- •- Severe or uncontrolled concomitant disease.
- •- Clinically active brain metastases defined as symptomatic or requiring treatment.
研究者
相似试验
未知
1 期
Phase 1 study of DS-1123aAdvanced solid tumor that is refractory to standard treatment, or for which no standard treatment is available.JPRN-jRCT2080223031DAIICHISANKYO Co.,Ltd.27
已完成
1 期
A Phase 1, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti- tumor Activity of AZD9833 in Japanese Women with ER Positive, HER2 Negative Advanced Breast CancerAdvanced Breast CancerJPRN-jRCT2080225373AstraZeneca KK12
进行中（未招募）
1 期
An Open-Label Phase 1 Study of Ceralasertib in Japanese Patients with Advanced Solid MalignanciesAdvanced solid malignanciesJPRN-jRCT2031220106Yamaji Shigeyuki18
已完成
1 期
A Phase I, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of MEDI9447 (Oleclumab) in Japanese Patients with Advanced Solid MalignanciesAdvanced Solid MalignanciesJPRN-jRCT2080224133AstraZeneca12
已完成
1 期
A Phase I, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of AZD9150 Monotherapy and AZD9150 in Combination With Durvalumab in Japanese Patients With Advanced Solid MalignanciesAdvanced Solid MalignanciesJPRN-jRCT2080223819AstraZeneca KK9